BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: Within the CD34+ population, however, the BP-CML cells were significantly more sensitive than the healthy CD34+ cells to BCL-xL inhibition in combination with either BCL-2 (healthy: 26.58 ± 11.02% cell death; BP-CML: 60.20 ± 17.55%; p = 0.0077) or MCL-1 (healthy: 41.32 ± 16.19%; BP-CML: 77.09 ± 16.78%; p = 0.0043).